Status:

RECRUITING

Fenofibrate in Patients With Cervical Intraepithelial Neoplasia and Invasive Cervical Carcinoma

Lead Sponsor:

Lindsay Ferguson, MD

Conditions:

Cervical Intraepithelial Neoplasia

Invasive Cervical Cancer

Eligibility:

FEMALE

18+ years

Phase:

PHASE1

Brief Summary

Normally, p53 helps prevent tumors from forming in the body. Early studies have shown that Fenofibrate, a cholesterol-lowering drug, can restore normal function to p53 and can change the metabolism of...

Eligibility Criteria

Inclusion

  • Participants must have histologically or cytologic confirmed high grade dysplasia or cervical cancer. Histologic types include squamous cell, adenocarcinoma or adenosquamous cell carcinoma.
  • Participants must be eligible for surgical management with LEEP, CKC or hysterectomy or chemoradiation
  • Age ≥ 18 years
  • Normal liver function (AST, ALT, bilirubin within institutional normal limits).
  • Participants must be English speaking
  • Participants must have the ability to understand and the willingness to sign a written informed consent document.

Exclusion

  • Participants with active liver disease, including primary biliary cirrhosis and unexplained, liver function abnormality
  • Participants with severe kidney impairment (CrCl ≤30 mL/min calculated using Cockcroft-Gault), or end-stage kidney disease on dialysis
  • Participants with preexisting gallbladder disease including active gallstones
  • Known hypersensitivity to fenofibrate or fenofibric acid
  • Participants that are pregnant or breast feeding due to unknown risk to developing fetus/infant. Please note: Participants of child-bearing potential (have had menses within the past year or have not had total hysterectomy) are actively screened for pregnancy prior to diagnostic procedures and screened again prior to treatment.

Key Trial Info

Start Date :

November 20 2024

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

November 30 2026

Estimated Enrollment :

24 Patients enrolled

Trial Details

Trial ID

NCT06191133

Start Date

November 20 2024

End Date

November 30 2026

Last Update

October 2 2025

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

University Hospitals Cleveland Medical Center, Case Comprehensive Cancer Center

Cleveland, Ohio, United States, 44106